Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
Purpose. This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity.
Patients and Methods. Eligible patients had metastatic adenocarcinoma of the colon or rectum. Patients received perillyl alcohol orally at a dose of 1200 mg/m2. Dose escalation to 1,600mg/m2 was allowed.
Results. Twenty-seven patients were enrolled. The median time to progression was 1.8 months (range 1 to 3 mo). Four patients received less than one cycle and were not evaluable for response. Of the remaining 23, all had progressive disease. There were no complete or partial responses. Toxicity was relatively mild, with fatigue, nausea and anemia predominating. Three patients withdrew from therapy for toxicity (grade 3 belching, bloating; grade 2 nausea, fatigue, vomiting, anorexia and increase perspiration; grade 1 anorexia).
Discussion. Despite preclinical evidence of anticancer activity, oral perillyl alcohol administered at this dose and formulation does not appear to have clinical antitumor activity when used for patients with advanced colorectal carcinoma.
Key WordsPerillyl alcohol monoterpenes colon cancer
Jemel A, Thomas A, Murray T. Cancer Statistics 2002. CA Cancer J Clin
Cunningham D, Pyrhnen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet
Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan plus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer. Lancet
Douillard J-Y, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med
Maindraul-Goebel F, Louvet C, Andr T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FLOFOX6). European Journal of Cancer
De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol
Gauccgettu S, Perpoint B, Zidani R, et al. Phase III multi-center randomized trial of oxaliplatin added to chronomo ulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol
Crowell PL and Gould MN. Chemoprevention of mammary cancer by monoterpenoids. Crit Rev Oncogenesis 1994;5:1–22.PubMedGoogle Scholar
Reddy BS, Wang C-X, Samalha H, et al. Chemoprevention of colon carcinogenesis by dietary perilly alcohol. Cancer Res
Huanbiao LH, Hadisusilo S, Qureshi AA, and Elson CE. Isopreniods suppress the growth of murine B16 melanoma in vitro and in vivo. J Nutr
Mills J, Chari R, Boyer I, Gould M, Jirtle R. Induction of apoptosis in liver tumors by the monopterene perilly alcohol. Cancer Res
Ariazi E, Salomi Y, Ellis M, et al. Activation of the transforming growth factor β signaling pathway and induction of cytostasis and apoptosis in mammary carcinoma treated with the anticancer agent perilly alcohol. Cancer Res
Crowell PL, Chang RR, Ren Z, Elson C, Gould MN. Selective inhibition of isoprenylylation of 21–26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem
Ripple G, Gould M, Aroomanian R, et al. Phase I clinical and pharmacokinetic study of perilly alcohol administered four times a day. Clin Ca Res
Hudes GR, Szarka CE, Adama A, et al. Phase I pharmacokinetic trial of perilly alcohol (NSC 641066) in patients with refractory solid malignancy. Clin Ca Res Vol
Ripple GH, Gould MN, Stewart JA, et al. Phase I clinical trial of perilly alcohol administered daily. Clin Ca Res
Crowell PL. Monoterpenes in breast cancer chemoprevention. Breast Cancer Research and Treatment
Kato K, Cox AD, Hiska MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA
Huluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer
Gelb MH, Tamamoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN. The inhibition of protein prenyltransferases by oxygenated metabolites of limone and perillyl alcohol. Cancer Lett
Eummer JT, Gibbs BS, Zahn TJ, Sebolt-Leopold JS, Gibbs R. Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg Med Chem
Hohl RJ. Monoterpenes as regulators of malignant cell proliferation. Advances in Exp Med and Bio
Lantry LE, Zhang Z, Crist KA, et al. Chemopreventive efficacy of promising farnesyl transferase inhibitors. Exp Lung Res
Bailey HH, Levy D, Harris LS, et al. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecologic Oncology